Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination : The Pediatric Infectious Disease Journal

Secondary Logo

Journal Logo

CME REVIEW ARTICLE

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

ZANGWILL, KENNETH M. MD; BELSHE, ROBERT B. MD

Author Information
The Pediatric Infectious Disease Journal 23(3):p 189-197, March 2004. | DOI: 10.1097/01.inf.0000116292.46143.d6

Abstract

Increasing use of influenza vaccine in children is expected as this important virus becomes more widely recognized as a major cause of morbidity in young children. Clinicians and third party payers must consider the implications of national vaccine use recommendations, with their current focus on young children, on their practices and on the community at large. Two influenza vaccines are available in the United States, an inactivated, trivalent intramuscular formulation (TIV) which is approved for use among children ≥6 months of age; and a live, attenuated intranasal trivalent preparation (LAIV) indicated for healthy persons 5 to 49 years of age. This review summarizes available data regarding the safety and efficacy of TIV, in comparison with LAIV, with particular attention to children <9 years of age, the population for whom two doses of vaccine are recommended for first time vaccination. It is apparent that relatively few data are available on the safety of TIV in young children, that important age-specific differences in TIV vaccine efficacy exist and that LAIV appears similar to TIV with regard to safety and efficacy in younger children, but no head-to-head comparison of these two licensed products is available.

© 2004 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid